Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2019, Vol. 24 ›› Issue (9): 1065-1069.doi: 10.12092/j.issn.1009-2501.2019.09.016

Previous Articles     Next Articles

Progress in basic research and clinical application of CDK4/6 inhibitor in tumor therapy

WU Limei, CHENG Liyan, ZHENG Xiaoliang, WANG Xiaoju   

  1. Center for Molecular Medicine, Zhejiang Academy of Medical Sciences, Hangzhou 310013, Zhejiang,China
  • Received:2019-04-02 Revised:2019-04-28 Online:2019-09-26 Published:2019-09-26

Abstract:

Cyclin-dependent kinase 4/6 (CDK4/6) is a serine/threonine kinase that regulates the phosphorylation state of retinoblastoma protein (Rb) by binding to cyclin D.Phosphorylated Rb releases E2F that freely activates a series of gene expression to participate in DNA replication and cell division, which mediates cell G1/S phase transition, affects the progression of the cell cycle. Recent studies have found that CDK4/6 plays a central role in tumorigenesis and development, and has become an important molecular target for clinical treatment of various tumors. This article will review the latest research progress in the relationship between CDK4/6 and tumors and the clinical application of CDK4/6 inhibitors.

Key words: cyclin-dependent kinase 4/6, cyclin D, CDK4/6 inhibitors, tumor targeted therapy

CLC Number: